Oncology therapy

Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol 2004 15 858-862. 

Some PNS cases run an indolent natural course [232], or the PNS may improve spontaneously [233]. Spontaneous remission should always be considered when patients seem to improve by oncological therapy or immunomodulation. 

ONCOLOGY THERAPY FOR THE LATE-STAGE CANCER PATIENT... 

For example, a novel oncology therapy with a good (expected) safety profile relative to currently available therapies might be required to show a 20% improvement in median survival in subjects who have shown progression of disease after treatment with the best currently approved therapies. Because of the lack of effective alternatives for these subjects and assuming that a clean safety profile is established, an 80% confidence interval may be deemed adequate providing the lower bound does not include 0% improvement. 

Gao Z, Garcia-Echeverria C, Jensen MR (2010) Hsp90 inhibitors clinical development and future opportunities in oncology therapy. Curr Opin Drug Discov Dev 13(2) 193-202... 

These agents are useful in the therapy of hypertension and angina (see Table). Cardio-selective drugs (e.g., verapamil) may be useful in the therapy of arrhythmias. Lesser uses include therapy of drug resistance in oncologic therapy (e.g., verapamil) and prevention of ischemic damage in stroke victims (e.g., lipophilic drugs such as nimodipine). 

Ewesuedo RB, Ratain MJ. Principles of cancer chemotherapy. In Yokes EE, Golomb HM (ed). Oncologic Therapies. Springer, New York. 2003 pp. 19-67. 

Response to therapy is usually measured using the RECIST criteria [59, 60] for morphologic images (MRI, CT, ultrasound). Tumor sizes, however, do not necessarily reflect the number of viable tumor cells. From other types of oncologic therapy (e.g. chemotherapy) it is known that, in the early post-treatment period, the size of the tumor lesions remains constant even though the number of vi-... 

Lenihan and Cardinale (2012) grouped the multiple potential cardiovascular complications of oncologic therapy into three main categories ... 

As noted previously, cardiac dysfunction and heart failure are potentially common late effects of oncologic therapy (Lenihan and Cardinale 2012). The authors emphasized the importance of the latter category precisely because of the benefits of early identification and appropriate intervention. Cardinale and colleagues (2015) conducted a prospective study addressing the early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. In the study, including 2,625 participants initially, individuals were followed up after the last dose of anthracy-cline-containing therapy the median follow-up period was 5.2 years (range 4 months to 19 years). Two hundred and twenty-five (9 %) participants were lost to follow-up. Of the rest, cardiotoxicity occurred in 226 (9 %). The median time between cessation of treatment and the development of cardiotoxicity was 3.5 months. 

The classic oncological therapies, such as surgery, chemotherapy, radiation therapy and administration of analgesics, also target bone metastases and their clinical symptoms. In this setting, the time and effort of any therapy and its direct consequences. 

---